Microbioma intestinal y obesidad: Mecanismos fisiopatológicos, evidencia clínica y perspectivas biotecnológicas para su modulación terapéutica
Sapiens in Medicine Journal · 11.07.2026 · 4 (3) · 1-16
DOI: 10.71068/3cpsha32 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sapiens in Medicine Journal, online erschienen am 11.07.2026. Verfasst von Daniela Anahí Baldeón Ríos und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity has been conceptualized as a public health problem of growing magnitude, associated with chronic non-communicable diseases characterized by high morbidity and mortality. Recent scientific evidence has demonstrated that the gut microbiome plays an active role in regulating energy metabolism, adipose tissue homeostasis, and low-grade systemic inflammation—processes all implicated in the pathogenesis of obesity. The general objective of this study was to analyze published scientific evidence regarding the relationship between the gut microbiome and obesity, identifying the involved pathophysiological mechanisms and the microbiome modulation strategies described in the literature. A narrative review was conducted of scientific literature published between 2016 and 2026 using the PubMed, Scopus, and Google Scholar databases; controlled descriptors (DeCS/MeSH) combined with Boolean operators were employed, and 25 sources meeting the inclusion criteria were selected. The main results synthesized from the review were: (i) the identification of a consistent dysbiotic profile in obesity, characterized by reduced microbial diversity, an increased Firmicutes/Bacteroidetes ratio, and a decrease in butyrate-producing bacteria; (ii) the confirmation of a causal link between the microbiome and obesity through studies using germ-free models and microbiota transplantation; (iii) the demonstration that strategies such as fecal microbiota transplantation, probiotics (including next-generation probiotics based on Akkermansia muciniphila, prebiotics, and dietary modification yield metabolic improvements, albeit heterogeneous ones; and (iv) the identification of biotechnological prospects such as the engineering of therapeutic bacteria, the development of postbiotics, and the application of artificial intelligence to microbiome analysis. It was concluded that gut dysbiosis constitutes an active component of obesity pathogenesis and that its modulation represents a promising therapeutic avenue, although further clinical trials with greater methodological rigor are still required.
Zitieren
APA
Ríos, D. A. B., Ríos, D. G. B., & Jumbo, S. J. C. (2026). Microbioma intestinal y obesidad: Mecanismos fisiopatológicos, evidencia clínica y perspectivas biotecnológicas para su modulación terapéutica. Sapiens in Medicine Journal, 4(3), 1-16. https://doi.org/10.71068/3cpsha32
Vancouver
Ríos DAB, Ríos DGB, Jumbo SJC. Microbioma intestinal y obesidad: Mecanismos fisiopatológicos, evidencia clínica y perspectivas biotecnológicas para su modulación terapéutica. Sapiens in Medicine Journal. 2026;4(3):1-16. doi:10.71068/3cpsha32
BibTeX
@article{Ros2026,
author = {Ríos, Daniela Anahí Baldeón and Ríos, Diego Gabriel Baldeón and Jumbo, Sandra Jeanneth Cueva},
title = {Microbioma intestinal y obesidad: Mecanismos fisiopatológicos, evidencia clínica y perspectivas biotecnológicas para su modulación terapéutica},
journal = {Sapiens in Medicine Journal},
year = {2026},
volume = {4},
number = {3},
pages = {1--16},
doi = {10.71068/3cpsha32}
}
EUVIMED